Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2226-2235

  Ruban, Angela ^a   Berkutzki, Tamara ^a   Cooper, Itzik ^a   Mohar, Boaz ^a   Teichberg, Vivian I ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Blood glutamate scavengers; Gliomas; Glutamate oxaloacetate transferase

Indexed keywords

ASPARTATE AMINOTRANSFERASE; OXALOACETIC ACID; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASPARTATE AMINOTRANSFERASES; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; GLIOMA; GLUTAMIC ACID; HUMANS; MALE; MICE; MICE, NUDE; OXALOACETIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TUMOR BURDEN;

EID: 84875540208     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9794-x     Document Type: Article

References (35)

1. de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59(8):1181-1189
2. Sontheimer H (2003) Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 26 (10):543-549
3. Sontheimer H (2004) Ion channels and amino acid transporters support the growth and invasion of primary brain tumors. Mol Neurobiol 29(1):61-71
4. Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383-4391
5. Ye ZC, Rothstein JD, Sontheimer H (1999) Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19(24):10767-10777
6. Behrens PF et al (2000) Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol 47(1):11-22
7. Rijpkema M et al (2003) Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 16(1):12-18
8. Roslin M et al (2003) Baseline levels of glucose metabolites, gluta-mate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61(2):151-160
9. Chung WJ et al (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25(31):7101-7110
10. Takano T et al (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7(9):1010-1015
11. Ishiuchi S et al (2007) Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27 (30):7987-8001
12. Arcella A et al (2005) Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 7(3):236-245
13. Ishiuchi S et al (2002) Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8(9):971-978
14. Lyons SA et al (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67(19):9463-9471
15. Ikonomidou C, Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1(6):383-386
16. Cohen-Kashi-Malina K, Cooper I and Teichberg VI Mechanisms of glutamate efflux at the blood-brain barrier: involvement of glial cells. J Cereb Blood Flow Metab
17. Teichberg VI et al (2009) Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuro-pathologies. Neuroscience 158(1):301-308
18. Berl S, Lajtha A, Waelsch H (1961) Amino acid and protein metabolism of the brain. VI. Cerebral compartments of glutamic acid metabolism. J Neurochem 7:186-197
19. Gottlieb M, Wang Y, Teichberg VI (2003) Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 87(1):119-126
20. Zlotnik A et al (2009) The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 21(3):235-241
21. Zlotnik A et al (2008) The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 33(6):1044-1050
22. Zlotnik A et al (2007) Brain neuroprotection by scavenging blood glutamate. Exp Neurol 203(1):213-220
23. Campos F, et al. Neuroprotection by glutamate oxaloacetate trans-aminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab
24. Philip M et al (2009) Methodological quality of animal studies of neuroprotective agents currently in phases II/III acute ischemic stroke trials. Stroke 40(2):577-581
25. Campos F, et al. (2011) High blood glutamate oxaloacetate trans-aminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab published on line
26. Castillo J et al (1996) Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27(6):1060-1065
27. Burckhardt BC et al (2005) Substrate specificity of the human renal sodium dicarboxylate cotransporter, hNaDC-3, under voltage-clamp conditions. Am J Physiol Renal Physiol 288(4): F792-F799
28. Pajor AM, Gangula R, Yao X (2001) Cloning and functional characterization of a high-affinity Na(+)/dicarboxylate cotrans-porter from mouse brain. Am J Physiol Cell Physiol 280(5): C1215-C1223
29. Haussinger D et al (1989) Hepatocytes heterogeneity in glutamate metabolism and bidirectional transport in perfused rat liver. Eur J Biochem 185(1):189-195
30. Kollareddy M et al (2008) Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152(1):27-33
31. Loh JK, et al. Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer 10: p 268
32. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3 (5):430-446
33. Oka A et al (1993) Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 13 (4):1441-1453
34. Augustine CK et al (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15(2):502-510
35. Ma D, Rajakumaraswamy N, Maze M (2004) alpha2-Adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull 71:77-92